Hematological Neoplasms

Tecartus (brexucabtagene autoleucel) has emerged as a revolutionary CAR-T cell therapy, gaining approval from the U.S. Food and Drug Administration (FDA) for the treatment of two critical hematologic malignancies.

Autologous and allogeneic stem cell transplantation (auto-SCT and allo-SCT) represent potential curative approaches for patients with T-cell lymphomas.

In early June 2024, the results of a Phase I clinical trial for the CD7-CAR-T product PA3-17 in the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (r/r T-ALL/LBL) were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

The initial list price for Yescarta was set at approximately $373,000 per treatment.

Kymriah is a gene therapy treatment developed by Novartis Pharmaceuticals for certain types of blood cancers. It works by reprogramming the patient’s T cells to target and destroy cancer cells.

The National Cancer Institute (NCI) in the USA was the first to report a successful case of second-generation CD19 CAR-T cell therapy.

Kymriah, also known as tisagenlecleucel, is a revolutionary treatment in the field of oncology, specifically designed for certain types of blood cancers.

Kymriah therapy, also known as tisagenlecleucel, represents a groundbreaking advancement in the field of oncology.